Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study

References

• Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation. 2017;136(12):1114–1122. doi:10.1161/CIRCULATIONAHA.116.027094
   PubMed Web of Science ®Google Scholar
• Arend WP, Michel BA, Bloch DA, et al. The American college of rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–1134. doi:10.1002/art.1780330811
   PubMed Web of Science ®Google Scholar
• Pedreira ALS, Santiago MB. Association between Takayasu arteritis and latent or active mycobacterium tuberculosis infection: a systematic review. Clin Rheumatol. 2020;39(4):1019–1026. doi:10.1007/s10067-019-04818-5
   PubMed Web of Science ®Google Scholar
• Carvalho ES, De Souza AW, Leao SC, et al. Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. Clin Rheumatol. 2017;36(1):205–208. doi:10.1007/s10067-016-3400-0
   PubMed Web of Science ®Google Scholar
• Thapa Magar M, Kafle S, Poudel A, et al. Takayasu's arteritis and its association with mycobacterium tuberculosis: a systematic review. Cureus. 2021;13(8):e16927.
   PubMed Web of Science ®Google Scholar
• Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70(7):677–682. doi:10.1136/thoraxjnl-2014-206470
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Capone A, et al. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019;18(5):415–425. doi:10.1080/14740338.2019.1612872
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509. doi:10.1016/j.autrev.2015.01.011
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Nikiphorou E, Dey M, et al. EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742–753. doi:10.1136/ard-2022-223335
   PubMed Web of Science ®Google Scholar
• Xie X, Chen JW, Li F, et al. A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy. Clin Exp Med. 2011;11(3):155–161. doi:10.1007/s10238-010-0123-4
   PubMed Web of Science ®Google Scholar
• Ruan Q, Zhang S, Ai J, et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis. Clin Rheumatol. 2016;35(2):417–425. doi:10.1007/s10067-014-2817-6
   PubMed Web of Science ®Google Scholar
• Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON-TB gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis. 2009;13(11):1427–1432.
   PubMed Web of Science ®Google Scholar
• Li J, Zheng W, Yang Y, et al. Clinical characteristics of adult patients with systemic vasculitis: data of 1348 patients from a single center. Rheumatol Immunol Res. 2021;2(2):101–112. doi:10.2478/rir-2021-0014
   PubMedGoogle Scholar
• Baliashvili D, Blumberg HM, Benkeser D, et al. Association of treated and untreated chronic hepatitis C with the incidence of active tuberculosis disease: a population-based cohort study. Clin Infect Dis. 2023;76(2):245–251. doi:10.1093/cid/ciac786
   PubMed Web of Science ®Google Scholar
• Available from: https://icdc.chinacdc.cn/zcfgybz/bz/index_2.html
   Google Scholar
• Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1–11. doi:10.15585/mmwr.rr6901a1
   PubMed Web of Science ®Google Scholar
• Sun X, Wan S, Zhang L, et al. Prevalence and influencing factors of the high nil-control spot count in T-SPOT.TB: a matched case-control study. Clin Chim Acta. 2018;487:96–100. doi:10.1016/j.cca.2018.09.012
   PubMed Web of Science ®Google Scholar
• Available from: https://weekly.chinacdc.cn/
   Google Scholar
• Cao J, Liu S, Huang J. Risk factor for 31-day unplanned readmission to hospital in patients with pulmonary tuberculosis in China. Saudi Med J. 2021;42(9):1017–1023. doi:10.15537/smj.2021.42.9.20210281
   PubMed Web of Science ®Google Scholar
• Yang Y, Thumboo J, Tan BH, et al. The risk of tuberculosis in SLE patients from an Asian tertiary hospital. Rheumatol Int. 2017;37(6):1027–1033. doi:10.1007/s00296-017-3696-3
   PubMed Web of Science ®Google Scholar
• Nakao K, Ikeda M, Kimata S, et al. Takayasu's arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. Circulation. 1967;35(6):1141–1155. doi:10.1161/01.CIR.35.6.1141
   PubMed Web of Science ®Google Scholar
• Dong Z, Wang QQ, Yu SC, et al. Age-period-cohort analysis of pulmonary tuberculosis reported incidence, China, 2006–2020. Infect Dis Poverty. 2022;11(1):85. doi:10.1186/s40249-022-01009-4
   PubMed Web of Science ®Google Scholar
• Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13(4):R139. doi:10.1186/ar3453
   PubMed Web of Science ®Google Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717–722. doi:10.1086/506935
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang L, Zhang F, et al. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerg Microbes Infect. 2021;10(1):2303–2312. doi:10.1080/22221751.2021.2004864
   PubMed Web of Science ®Google Scholar
• Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009;61(3):300–304. doi:10.1002/art.24476
   PubMedGoogle Scholar
• Chen YJ, Wu CY, Shen JL, et al. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol. 2013;69(1):25–33. doi:10.1016/j.jaad.2012.12.966
   PubMed Web of Science ®Google Scholar
• Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207–228. doi:10.1080/1744666X.2019.1705785
   PubMed Web of Science ®Google Scholar
• Cho SK, Kim D, Won S, et al. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum. 2017;47(1):102–107. doi:10.1016/j.semarthrit.2017.01.004
   PubMed Web of Science ®Google Scholar
• Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis. 2015;74(6):1212–1217. doi:10.1136/annrheumdis-2013-204960
   PubMed Web of Science ®Google Scholar
• Evangelatos G, Koulouri V, Iliopoulos A, et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020;12:1759720X2093011. doi:10.1177/1759720X20930116
   Web of Science ®Google Scholar
• Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010.
   Google Scholar
• Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–639. doi:10.1002/acr.21641
   PubMed Web of Science ®Google Scholar
• Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006;8(4):R114. doi:10.1186/ar1994
   PubMed Web of Science ®Google Scholar
• Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl. 2014;91:24–31. doi:10.3899/jrheum.140099
   PubMedGoogle Scholar
• Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr. 2016;4(6):623–635. doi:10.1128/microbiolspec.TNMI7-0026-2016
   Web of Science ®Google Scholar
• Scrivo R, Sauzullo I, Mengoni F, et al. Mycobacterial interferon-gamma release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol. 2013;40(2):157–165. doi:10.3899/jrheum.120688
   PubMed Web of Science ®Google Scholar
• Wong SH, Gao Q, Tsoi KK, et al. Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71(1):64–72. doi:10.1136/thoraxjnl-2015-207811
   PubMed Web of Science ®Google Scholar
• Abubakar I, Drobniewski F, Southern J, et al. Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018;18(10):1077–1087. doi:10.1016/S1473-3099(18)30355-4
   PubMed Web of Science ®Google Scholar
• Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3–20. doi:10.1128/CMR.00034-13
   PubMed Web of Science ®Google Scholar
• Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012;142(1):63–75. doi:10.1378/chest.11-3157
   PubMed Web of Science ®Google Scholar
• Chandrashekara S, Panchagnula R, Chennupati Y. Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse. Rheumatology. 2023;62(12), 3952–3956.
   PubMedGoogle Scholar